Platelet-boosting drug for low counts from chemo
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a drug called hetrombopag that helps raise platelet counts in people with nasopharyngeal cancer who get low platelets from their chemotherapy. It may reduce the need for platelet transfusions and help you stay on your chemo schedule.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have nasopharyngeal cancer confirmed by biopsy or lab test.
- You are currently on a chemo regimen called gemcitabine plus cisplatin, and your platelet count dropped below 75 in the last cycle.
- You are expected to continue this same chemo for at least 2 more cycles.
- You have adequate kidney, liver, and blood cell function (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called hetrombopag to see if it can help prevent a drop in blood platelets (cells that help blood clot) caused by antibody-drug conjugate (ADC) cancer therapy. It may help patients who have already had low platelets from their treatment or are about to start an ADC regimen.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This trial tests whether a drug called hetrombopag can prevent dangerously low platelet counts (cells that help blood clot) in breast cancer patients receiving chemotherapy. It is for people who experienced very low platelets from a previous round of treatment.
This study tests a medicine called hetrombopag that may help raise your platelet count after chemotherapy for advanced lung cancer. It aims to prevent dangerously low platelet levels so you can continue your cancer treatment more safely.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.